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C-REACTIVE PROTEIN AND CORONARY CALCIUM SCORE  
ASSOCIATION IN CORONARY ARTERY DISEASE 
Ali Hosseinsabet(1), Ahmad Mohebbi(2), Alireza Almasi(3) 
 
Abstract 
 BACKGROUND: Both high-sensitivity C-reactive protein (hs-CRP) and spiral computed tomo-
graphy coronary artery calcium score (CCS) are valid markers of cardiovascular risk. It is un-
known whether hs-CRP is a marker of atherosclerotic burden or whether it reflects a process 
(eg, inflammatory fibrous cap degradation) leading to acute coronary events. 
 METHOD AND MATERIALS: In a cross-sectional study, we studied association between hs-CRP 
and coronary calcium score in 143 patients that were candidate for coronary artery bypass graft-
ing (CABG). 
 RESULTS: In our study, we found no significant association between hs-CRP and CCS in biva-
riants (P = 0.162) and multivariable (P = 0.062) analysis but in patients that didn’t take statins, 
this association was significant and positive in bivariant (P = 0.001) but in multivariant analysis 
this association was negative and significant (P = 0.008). 
 CONCLUSION: hs-CRP was not associated with CCS. The relation between CRP and clinical 
events might not be related to atherosclerotic burden. Markers of inflammation, like CRP, and 
indices of atherosclerosis, such as CAC, are likely to provide distinct information regarding car-
diovascular risk. 
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Many evidences suggest that inflammation plays a 
major role in the development of atherosclerosis and 
its clinical manifestations.1,2 In some studies, plasma 
levels of inflammatory markers, particularly C-reactive 
protein (CRP), predict myocardial infarction and car-
diovascular death.3-8 However, CRP is associated with 
many established risk factors, including dyslipidemia, 
cigarette smoking, hypertension, diabetes and obesi-
ty9-15 and the relation between CRP and coronary ar-
tery disease (CAD) has been significant in some stu-
dies16-18 but in the others has not been significant17,19-27 
and even has been significantly negative.28,29 The ex-
tent to which CRP levels predict clinical events de-
pends on the relation of CRP to the burden of under-
lying atherosclerosis or the milieu leading to plaque 
rupture and thrombosis and is unknown. As CRP 
levels predict clinical events, study on the pathophysi-
ology of this relation is of interest to researchers. In 
contrast to clinical events, an independent association 
between CRP levels and coronary19-29 or carotid27,30-36 
atherosclerosis has not been established clearly. Co-
ronary artery calcification (CAC), measured by elec-
tron beam tomography (EBT), or spiral computed 
tomography might be useful in identifying novel risk 
factors for coronary atherosclerosis in asymptomatic 
subjects. The amount of CAC at EBT is correlated 
with the burden of atherosclerosis at both autopsy 
and coronary angiography,37,38 and studies suggest 
that CAC is a predictor of clinical CAD events in 
both symptomatic39 and asymptomatic40,41 subjects. 
Studies on CAC might permit differentiation of fac-
tors associated with coronary atherosclerosis from 
those related to plaque rupture or thrombosis. 
 Studies on CRP and CAC in healthy subjects have 
produced conflicting results. Whereas some found no 
association between CRP and CAC,17-29 others have 
reported a weak relation.16-18 It is unclear whether 
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these conflicting reports reflect the limitations of 
study design and analysis or real differences in the 
pathophysiology of CAC, a measure of coronary athe-
rosclerotic burden, and elevated CRP, a marker of 
inflammation. 
 Some studies support the concept that CAC 
scores and plasma CRP levels might provide inde-
pendent and complementary information regarding 
the risk of cardiovascular events.22,42 
Materials and Methods 
The study population was 143 patients with coronary 
artery disease admitted to Shaheed Rajaei Cardiovas-
cular Center, an academic tertiary referral center, since 
December 2006 to Mars 2007 for coronary artery by-
pass grafting.  
 
Exclusion criteria: 1- History of myocardial infarction 
or unstable angina at previous month; 2- Past history 
of aortic valve replacement or mitral valve replacement; 
3- Past history of CABGs or coronary stenting   
 All study participants were given written informed 
consent. The protocol was approved by the Research 
Committee at the Iran University of Medical Science, 
Tehran. Age, cardiac risk factors including hyperten-
sion, dyslipidema, diabetes mellitus, smoking, family 
history of coronary disease, and drug history were 
determined by interview (self-reported), and body 
mass index (BMI) by examination.  
 Blood sampling was done for measuring lipid  
profile, creatinine44-46 and hs-CRP and then samples 
were frozen at -70˚C for four months. hs-CRP was 
measured via commercial kits (Pars Azmun Co.), by 
latex immunoturbid assay and by a single laboratory 
technician blinded to all clinical 
 
and radiologic data. Other clinical tests including lipid 
profile, creatinine, and coronary calcium scoring by 10 
slice spiral CT scan (Siemens Somatom Sensation 10) 
was done. Calcium score of coronary artery expressed 
according to Agston et al work43 that previously ex-
plained. A total CAC score was determined from the 
sum of individual scores of the 4 major epicardial co-
ronary arteries. All scans were interpreted by a single 
radiologist blinded to all clinical and serologic data. 
 Data were analyzed by SPSSv15/Win and reported 
as, mean ± SD if continuous, and as proportions if 
categorical. Because some variables were not normal 
distributed, we transformed them to logarithmic for 
normalization of data and because some patients have 
CCS = 0, log (CCS + 1) was substituted. Firstly, we 
assessed association between coronary calcium score 
[log CCS + 1] and log (hs-CRP) overall by Pearson 
correlation coefficient and then bivariant in presence 
of any risk factors, any drug usage and in both sex by 
this method. Because almost all patients used aspirin 
and beta blockers, and neglectable percents of pa-
tients used calcium channel blockers or gemfibrozil, 
we did not enter them in our analysis. Secondly, we 
assessed this correlation by multivariable enter linear 
regression in overall and then in men and women and 
then according to statin usage. We entered age, BMI, 
drug history, all risk factors, lipid profile and creati-
nine in multivariable analysis. 
Results 
Table 1 shows demographic characteristics, CRP le-
vels, and CCS scores in the subjects (n = 143).  
 Bivariant analysis of CRP and CCS in all patients and 
subgroups are presented in table 2. This correlation was 
not significant in all of the patients (r = -0.118, P = 0.162). 
In 60-69 years old patients (r = 0.327, P = 0.031) and in 
patients were not on statins (r = 0.442, P = 0.001), this 
correlations were moderate and significant. In other 
subgroups this correlation was not significant.  
 Factors that were associated with CCS, when C - 
reactive protein is not included in fully adjusted, mul-
tivariable linear regression are shown in Table 3. Age, 
male sex and family history of coronary artery disease 
were positive predictors of CCS. 
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Table 1. Characteristics of the study sample 
Age, year 
                  <50 
               50-59 
               60-69 
                  >70  






                <24.99 
               25-29.99 





TG, mg/dl 153.6 ± 78.2 
Cholesterol, mg/dl 171.4 ± 48.8 
LDL, mg/dl 94.0 ±31.4 
HDL, mg/dl  41.0 ± 37.9 
CR, mg/dl 1.37 ± 0.95 
hs-CRP, mg/dl 2.89 ± 3.43 









*Values are mean ± SD, or percent. 
†(BMI = Body Mass Index, TG = Triglyceride, LDL = Low 
Density Lipoprotein, HDL = High Density Lipoprotein,  
CR = CReatinine , hs-CRP = high sensitive CRP, CCS = Coro-
nary Calcium Score, HTN = Hypertension, DLP = Dyslipidemia, 
DM = Diabetes Mellitus, C/S = Cigarette Smoking, FH = Family 
History of coronary artery disease, ACEI/ARB = Angiotensin 
Converting Enzyme Inhibitor/ Angiotensin Receptor Blocker) 
 
Table 2. Correlation of log( hs-CRP) and log (CCS+1) in 
all cases and subgroups 
GROUP r P 
MALE 0.122 0.213 
FEMALE 0.037 0.828 
HTN(+) 0.144 0.339 
HTN(-) 0.118 0.248 
DLP(+) 0.091 0.469 
DLP(-) 0.136 0.236 
DM(+) 0.176 0.236 
DM(-) 0.096 0.353 
FH(+) 0.101 0.673 
FH(-) 0.101 0.267 
C/S(+) 0.144 0.318 
C/S(-) 0.110 0.296 
ACEI/ARB(+) 0.091 0.442 
ACEI/ARB(-) 0.132 0.281 
STATIN(+) 0.006 0.958 
STATIN(-) 0.442 0.001 
Age            <50 
               50-59 
               60-69 









BMI       <24.99 
           25-29.99 







ALL CASES - 0.118 0.162 
* (+) is presence the condition and (–) is absence the condition 
 
Table 3. Multivariable Analysis of Factors Associated with 
Coronary Calcium Score when C - reactive protein is not 
included in analysis. 
   B SD P 
(Constant) 1.173 1.323 0.377 
AGE 0.034 0.008 0.000 
SEX - 0.409 0.191 0.035 
HTN 0.304 0.177 0.089 
DLP 0.019 0.163 0.909 
DM 0.121 0.165 0.464 
FH 0.470 0.212 0.028 
C/S 0.058 0.172 0.735 
ACEI/ABR - 0.069 0.153 0.651 
STATIN - 0.146 0.157 0.355 
LDL 0.000 0.003 0.859 
LogHDL 0.138 0.184 0.455 
LogTG - 0.182 0.159 0.257 
LogCR - 0.134 0.252 0.598 
BMI - 0.014 0.021 0.514 
*Results of linear regression (log of (CCS + 1) as the dependent 
variable) are presented when CRP is not included in analysis, as 
the change log (CCS + 1) for a specific change in risk factor. 
Models were adjusted for the following variables; age, sex, histo-
ry of hypertension, history of dyslipidemia, diabetes mellitus, 
family history of coronary artery disease, smoking, use of the 
following medications: statins, ACEI/ARB ,LDL [log LDL], 
HDL [log HDL] ,TG [log TG] ,CR [log CR], body mass index. 
 
 Factors that were associated with CCS, when C- 
reactive protein is included, in fully adjusted, multiva-
riable linear regression are shown in Table 4. Age was 
only predictor of CCS in presence of CRP and sex 
and family history of coronary artery disease were not 
Table 4. Multivariable Analysis of Factors Associated with 
Coronary Calcium Score when C - reactive protein is in-
cluded in analysis. 
  B SD P 
(Constant) 1.046 1.312 0.427 
AGE 0.037 0.008 0.000 
SEX - 0.343 0.193 0.078 
HTN 0.293 0.176 0.099 
DLP - 0.005 0.161 0.977 
DM 0.141 0.164 0.392 
FH 0.395 0.213 0.067 
C/S 0.068 0.170 0.688 
ACEI/ABR - 0.032 0.153 0.834 
STATIN - 0.204 0.158 0.200 
LDL 0.001 0.003 0.657 
LogHDL 0.089 0.184 0.630 
LogTG - 0.169 0.158 0.288 
LogCR - 0.063 0.253 0.802 
BMI - 0.013 0.021 0.542 
LogCRP - 0.115 0.061 0.062 
*Results of linear regression (log of (CCS + 1) as the dependent 
variable) are presented when CRP is included in analysis as the 
change log (CCS + 1) for a specific change in risk factor. Models 
were adjusted for the following variables; age, sex, history of 
hypertension, history of dyslipidemia, diabetes mellitus, family 
history of coronary artery disease, smoking, use of the following 
medications: statins, ACEI/ARB ,LDL [log LDL] ,HDL [log HDL] 
,TG [log TG] ,CR [log CR], body mass index and CRP [log CRP]. 
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Table 5. Multivariable Analysis of Factors Associated with 
Coronary Calcium Score C - reactive protein in patients did 
not use statin 
 
 B SD P 
(Constant) 3.774 1.682 0.031 
AGE 0.021 0.012 0.088 
SEX - 0.653 0.262 0.017 
HTN 0.318 0.259 0.227 
DLP 0.086 0.243 0.724 
DM 0.250 0.226 0.276 
FH 0.682 0.318 0.038 
C/S - 0.346 0.275 0.215 
ACEI/ABR 0.191 0.231 0.414 
LDL 0.004 0.004 0.294 
LogHDL 0.188 0.219 0.396 
LogTG - 0.261 0.241 0.285 
LogCR - 0.531 0.292 0.077 
BMI - 0.068 0.037 0.077 
LogCRP - 0.278 0.100 0.008 
*Results of linear regression (log of (CCS + 1) as the dependent 
variable) are presented in patients that not use statin, as the 
change log (CCS + 1) for a specific change in risk factor. Mod-
els were adjusted for the following variables; age, sex, history 
of hypertension, history of dyslipidemia, diabetes mellitus, 
family history of coronary artery disease, smoking, use of the 
following medications: statins, ACEI/ARB ,LDL [log LDL], 
HDL [log HDL], TG [log TG] ,CR [log CR], body mass index 
and CRP [log CRP]. 
 
predictors of CCS after adjustment for CRP level. 
Because in bivariants analysis the association of log 
(CRP) and log (CCS + 1) was significant in patient 
that were not on statins, we analyzed this association 
in fully adjusted, multivariable linear regression. Table 
5 shows this analysis. Male sex and family history of 
coronary artery disease are positive predictors of CCS, 
and CRP was negative predictor of CCS (P = 0.008) 
in patients that were on statins. 
Discussion  
CCS, measured at spiral CT, might be useful for iden-
tifying novel risk factors and exploring the relation of 
risk factors with coronary atherosclerosis. We have 
examined the association between plasma CRP and 
CCS in patients that were candidate for CABGs. In 
previous studies subjects were suspected to have co-
ronary artery disease without any documentation but 
in our study patients had coronary artery disease do-
cumented by selective coronary artery angiography. 
We found no evidence of a positive association be-
tween hs-CRP and calcium scores. Indeed these data 
suggest an inverse relationship between hs-CRP levels 
and coronary calcium in patients do not take statin. 
We believe that, lack of a positive association between 
hs-CRP and coronary calcium score needs careful 
consideration. The lack of correlation in the current 
data between spiral CT score and hs-CRP suggests 
that calcification may be less likely to reflect inflam-
mation per se. Spiral CT detected calcification may 
predominantly be a marker for mature and hence sta-
ble atherosclerotic plaque, and thus only can be an 
indirect marker for the presence of uncalcified rup-
ture-prone lesions, which may be probable markers 
for future cardiac events, but correlation between 
soft, noncalcified plaque and cardiac events was not 
confirmed.24 Deposition of calcium in atherosclerotic 
lesions has been shown to be an active process ana-
logous to the formation of bone spicules.47 Further-
more, it appears to involve cells of special embryonic 
lineage. 
 Therefore coronary calcification may not merely 
be a direct consequence of atherogenesis but may 
depend on the presence of specific determinants in-
dependent of the central processes involved in plaque 
formation. The reasons for the lack of association 
between CRP and CCS, in contrast to a more consis-
tent association between CRP and clinical events, are 
unclear. However, this finding supports the concept 
that CRP levels might not be related to atherosclero-
sis progression, distinct from being a marker of pla-
que rupture and thrombosis. Therefore, CRP might 
not be useful in identifying the underlying mechan-
isms of atherosclerosis initiation or progression. The 
present findings suggest that the relationship between 
higher CRP levels and incident cardiovascular events 
may reflect the composition, morphology, and stabili-
ty of plaque rather than overall atherosclerotic bur-
den.48 Because CCS are associated with risk for sub-
sequent cardiovascular events and provide a measure 
of disease processes distinct from CRP, these two 
markers may be complementary rather than competi-
tive for risk prediction.43  
 This study, demonstrate that hs-CRP is unrelated 
to the presence and severity of clinical calcified athe-
rosclerosis and suggests that serologic inflammatory 
markers are principally a measure of the atheroin-
flammatory disease process and are not an index of 
the extent of coronary atherosclerotic plaque. The 
independent prognostic utility of quantifying calcified 
atherosclerosis and systemic inflammation suggests 
that disease and process markers of atherosclerosis 
may be complementary tools in coronary heart dis-
ease prediction. 
 We used a validated commercial assay for the 
measurement of hs-CRP, but variability in commer-
cial assays may limit the validity of these data. We 
used CCS as a surrogate for coronary atherosclerotic 
plaque burden on the basis of the well-established 
relationship between CCS and the extent of histologic 
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plaque.37 However, atherosclerosis in vascular beds 
other than the coronary arteries could also contribute 
to the level of hs-CRP.49 
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